LYCOS RETRIEVER 
Haifa
built 658 days ago
The haptoglobin polymorphism testing patents have been assigned to HaptoGuard Ltd by Dr. Andrew Levy and the Rappaport Institute of Haifa, Israel. Dr. Andrew Levy, the company founder and Associate Professor at the Technion and Member of the Rapport Institute has demonstrated that the test represents the single most important predictor of risk for vascular disease among diabetics. Diabetic patients with the "favorable" haptoglobin polymorphism are far less likely to develop vascular disease, to die within 30 days of experiencing a myocardial infarction, or to manifest restenosis after angioplasty, compared to their peers with "unfavorable" genotypes.
Source:
MORE ABOUT
North Israel